CONCLUSIONS The new generation DES decreases SF, especially in the LAD. The ratio of SF is higher in RCA than LCA, and not improved even in new generation DES.
BACKGROUND Long stenting after first-generation drug-eluting stents (DES) implantation was associated with adverse cardiac events. However, it remains unclear whether long stenting after newer-generation DES implantation has an impact on clinical outcomes. Our aim was to compare clinical outcomes of the Nobori biolimus-eluting stent (BES) and the Xience/Promus cobalt chronium everolimus-eluting stent (CoCr-EES) in patients with de novo long coronary artery lesions.
METHODS A total of 2272 patients with 3146 lesions undergoing BES (1270 patients with 1751 lesions) and CoCr-EES (1002 patients with 1395 lesions) implantation between February 2010 and July 2012 were analyzed. Of these, 1310 patients with 1528 lesions (BES, 753 patients with 877 lesions; CoCr-EES, 557 patients with 651 lesions) had de novo coronary artery lesions, defined as total stent length !28 mm. We assessed the rates of major adverse cardiac events (MACE), defined as a composite of cardiac death, non-fatal myocardial infarction (MI), definite stent thrombosis, and clinically driven target lesion revascularization (TLR) within 2-year.
RESULTS Baseline patient and lesion characteristics were similar between BES and EES groups. Total stent length was not significant different between the 2 groups (44.7AE18.5mm vs. 46.2AE20.6mm, p¼0.13). The 2-year MACE rate was not significantly different between both groups (11.8% vs. 14.6%, p¼0.21). Cumulative incidence of cardiac death, MI, definite stent thrombosis, and clinically driven TLR rate were similar between the 2 groups (3.7% vs. 3.5%, p¼0.73; 1.3% vs. 1.1%, p¼0.76; 1.0% vs. 0.7%, p¼0.61; 8.4% vs. 11.6%, p¼0.09, respectively). Jong-Hwa Ahn, 1 Jeong Hoon Yang, 1 Kyu Tae Park, 1 Young Bin Song, 1 Joo-Yong Hahn, 1 Jin-Ho Choi, 1 Sang Hoon Lee, 1 Hyeon-Cheol Gwon, 1 Seung-Hyuk Choi 1 1 Samsung Medical Center, Seoul, Korea, Republic of BACKGROUND Limited data are available on long-term clinical outcomes of the second-generation drug-eluting stents (DES) compared with the first-generation DES in patients with coronary chronic total occlusion (CTO) undergoing percutaneous coronary intervention (PCI). The aim of this study is to compare the clinical outcomes of the second-generation DES with the first-generation DES for the treatment of CTO.
CONCLUSIONS
METHODS Between March 2003 and February 2012, 1,006 consecutive CTO patients who undergoing successful PCI using either first-generation DES (n ¼ 557) or second-generation DES (n ¼ 449) were enrolled in a multicenter, observational registry. Propensity-score matching was also performed. The primary outcome was cardiac death at 3-year follow-up.
